Takahisa Hanada
Overview
Explore the profile of Takahisa Hanada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fukushima K, Higashiyama H, Kazuta Y, Hashimoto K, Watanabe N, Furuya Y, et al.
Epilepsia Open
. 2023 Apr;
8(3):834-845.
PMID: 37052238
Objective: As of 2022, 36 anti-seizure medications (ASMs) have been licensed for the treatment of epilepsy, however, adverse effects (AEs) are commonly reported. Therefore, ASMs with a wide margin between...
2.
Hanada T
Biomolecules
. 2020 Mar;
10(3).
PMID: 32197322
It is widely accepted that glutamate-mediated neuronal hyperexcitation plays a causative role in eliciting seizures. Among glutamate receptors, the roles of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors in physiological...
3.
Wu T, Ido K, Ohgoh M, Hanada T
Epilepsy Res
. 2019 Apr;
154:42-49.
PMID: 31035244
Purpose: A number of antiepileptic drugs (AEDs) with a variety of modes of action, are effective in treating focal seizures. Several AEDs, such as perampanel (PER), levetiracetam (LEV), lacosamide (LCM),...
4.
Shibahara O, Watanabe M, Takamura Y, Yamada S, Akehi M, Sasaki T, et al.
J Med Chem
. 2019 Apr;
62(9):4780-4781.
PMID: 31002501
No abstract available.
5.
Kaji R, Imai T, Iwasaki Y, Okamoto K, Nakagawa M, Ohashi Y, et al.
J Neurol Neurosurg Psychiatry
. 2019 Jan;
90(4):451-457.
PMID: 30636701
Objective: To evaluate the efficacy and safety of intramuscular ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis (ALS). Methods: 373 patients with ALS (El Escorial definite or probable; laboratory-supported probable;...
6.
Shibahara O, Watanabe M, Yamada S, Akehi M, Sasaki T, Akahoshi A, et al.
J Med Chem
. 2017 Jul;
60(16):7139-7145.
PMID: 28753292
The retinoid X receptor (RXR) partial agonist 1-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]benzotriazole-5-carboxylic acid (1; CBt-PMN, E = 75%, EC = 143 nM) is a candidate for treatment of central nervous system (CNS) diseases such...
7.
Watanabe H, Watanabe K, Liu K, Hiramatsu S, Zeggar S, Katsuyama E, et al.
Mol Ther Methods Clin Dev
. 2017 Jun;
6:31-39.
PMID: 28649578
We evaluated the efficacy of a neutralizing anti-high mobility group box 1 (HMGB1) monoclonal antibody in MRL/ lupus-prone mice. The anti-HMGB1 monoclonal antibody (5 mg/kg weight) or class-matched control immunoglobulin...
8.
Wu T, Ido K, Osada Y, Kotani S, Tamaoka A, Hanada T
Epilepsy Res
. 2017 Jun;
137:152-158.
PMID: 28624183
Purpose: Status epilepticus (SE) causes irreversible neurodegeneration if not terminated quickly. Perampanel (PER), a potent AMPA receptor antagonist, has previously been shown to terminate seizures in the lithium-pilocarpine SE model....
9.
Wahyuningsih A, Shen L, Kobayashi K, Sasaki T, Takenaka F, Hanada T, et al.
Acta Med Okayama
. 2016 Feb;
70(1):13-24.
PMID: 26899605
Intact β2-glycoprotein I (iβ2GPI) is a glycoprotein that regulates coagulation and fibrinolysis. Nicked β2GPI (nβ2GPI) possesses an angiogenic property at a relatively low concentration, and an antiangiogenic property at a...
10.
Kobayashi T, Furusawa Y, Yamada S, Akehi M, Takenaka F, Sasaki T, et al.
ACS Med Chem Lett
. 2015 Mar;
6(3):334-8.
PMID: 25815156
RXR partial agonist NEt-4IB (2a, 6-[ethyl-(4-isobutoxy-3-isopropylphenyl)amino]pyridine-3-carboxylic acid: EC50 = 169 nM, E max = 55%) showed a blood concentration higher than its E max after single oral administration at 30...